2026-08-19T13:05:28.000Z · 6 weeks ago Revelation Biosciences selects Avance Clinical as CRO for Phase 2/3 Titan Study
Aug 19, 2026, 9:00 AM EDT · 6 weeks ago Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
Aug 6, 2026, 4:15 PM EDT · 1 month ago Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
2026-08-03T13:15:35.000Z · 2 months ago Revelation Biosciences announces results from market assessment for Gemini
Aug 3, 2026, 9:00 AM EDT · 2 months ago Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
Jul 21, 2026, 4:05 PM EDT · 2 months ago Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 10, 2026, 4:05 PM EDT · 2 months ago Revelation Biosciences Announces Adoption of Stockholder Rights Plan
2026-06-01T13:56:20.000Z · 4 months ago Revelation Biosciences adds two new members to AKI Advisory Board
Jun 1, 2026, 9:00 AM EDT · 4 months ago Revelation Biosciences Expands Acute Kidney Injury Advisory Board
2026-05-11T13:48:22.000Z · 4 months ago Revelation Biosciences reports FY25 EPS ($14.35) vs ($1,052.16) last year
May 11, 2026, 9:00 AM EDT · 4 months ago Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
May 7, 2026, 4:15 PM EDT · 4 months ago Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
2026-04-06T13:18:58.000Z · 6 months ago Revelation Biosciences announces formation of AKI advisory board
Apr 6, 2026, 9:00 AM EDT · 6 months ago Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
2026-03-30T19:56:44.000Z · 6 months ago Revelation Gemini data show ‘broad effect,’ says Roth Capital
2026-03-30T13:21:15.000Z · 6 months ago Revelation Biosciences presents additional data from Prime Clinical Study
Mar 30, 2026, 9:00 AM EDT · 6 months ago Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study
Mar 24, 2026, 9:00 AM EDT · 6 months ago REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
Mar 19, 2026, 9:00 AM EDT · 6 months ago Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
2026-02-27T13:39:33.000Z · 7 months ago Revelation Biosciences price target lowered to $16 from $20 at Roth Capital
Feb 26, 2026, 4:15 PM EST · 7 months ago Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
2026-01-30T21:10:32.000Z · 8 months ago Revelation Biosciences files to sell 4.27M shares of common stock for holders
Jan 26, 2026, 9:55 AM EST · 8 months ago Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026
Jan 23, 2026, 2:10 PM EST · 8 months ago Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds
2026-01-21T13:51:28.000Z · 8 months ago Revelation reaches agreement with FDA on Gemini approval pathway
Jan 21, 2026, 8:30 AM EST · 8 months ago Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI
Jan 14, 2026, 9:00 AM EST · 8 months ago Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)
Jan 12, 2026, 5:00 PM EST · 8 months ago Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jan 7, 2026, 9:00 AM EST · 8 months ago Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development
2025-12-01T14:15:23.000Z · 10 months ago Revelation Biosciences reaches quorum for Dec. 3 special meeting
Dec 1, 2025, 9:00 AM EST · 10 months ago Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting
2025-11-20T14:15:40.000Z · 10 months ago Revelation Biosciences on track for end-of-phase 1 meeting later this year
Nov 20, 2025, 9:00 AM EST · 10 months ago Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year
Nov 6, 2025, 4:15 PM EST · 11 months ago Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025
2025-10-29T13:15:56.000Z · 11 months ago Revelation Biosciences announces cancellation of Special Meeting
Oct 29, 2025, 9:00 AM EDT · 11 months ago Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date
Oct 15, 2025, 5:00 PM EDT · 11 months ago Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025
2025-09-16T21:20:13.000Z · 1 year ago Revelation Biosciences files to sell 13.07M shares of common stock for holders
2025-09-11T12:40:32.000Z · 1 year ago Revelation Biosciences announces exercise of warrants for $9.6M in proceeds
Sep 11, 2025, 8:30 AM EDT · 1 year ago Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
2025-09-10T11:30:36.000Z · 1 year ago Revelation Biosciences announces webcast to review Phase 1b PRIME data
Sep 10, 2025, 7:20 AM EDT · 1 year ago Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data
Sep 9, 2025, 4:55 PM EDT · 1 year ago Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
2025-09-09T12:35:01.000Z · 1 year ago Revelation Biosciences announces topline results from PRIME study
Sep 9, 2025, 8:00 AM EDT · 1 year ago Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study
Aug 8, 2025, 6:30 AM EDT · 1 year ago Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025
Jul 24, 2025, 9:00 AM EDT · 1 year ago Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research
Jul 16, 2025, 9:00 AM EDT · 1 year ago Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
Jul 1, 2025, 5:26 PM EDT · 1 year ago Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025
May 29, 2025, 4:05 PM EDT · 1 year ago Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering
May 29, 2025, 8:00 AM EDT · 1 year ago Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering
May 23, 2025, 4:05 PM EDT · 1 year ago Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors
May 8, 2025, 4:15 PM EDT · 1 year ago Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025
Apr 29, 2025, 9:00 AM EDT · 1 year ago Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients
Mar 17, 2025, 6:00 AM EDT · 1 year ago Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells
Mar 13, 2025, 6:00 AM EDT · 1 year ago Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference
Mar 6, 2025, 4:15 PM EST · 1 year ago Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024
Feb 26, 2025, 6:00 AM EST · 1 year ago Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
Feb 24, 2025, 6:00 AM EST · 1 year ago Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
Jan 24, 2025, 6:00 AM EST · 1 year ago Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025
Jan 21, 2025, 6:00 AM EST · 1 year ago Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
Jan 13, 2025, 6:00 AM EST · 1 year ago Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
Dec 3, 2024, 8:38 AM EST · 1 year ago Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
Dec 2, 2024, 6:00 AM EST · 1 year ago Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
Nov 12, 2024, 6:00 AM EST · 1 year ago Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
Nov 8, 2024, 4:15 PM EST · 1 year ago Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024